Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2004-08-05
2010-10-05
Lucas, Zachariah (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024100, C435S005000, C435S006120, C514S04400A
Reexamination Certificate
active
07807801
ABSTRACT:
A method of inhibiting replication of aflavivirusin animal cells, and an oligonucleotide compound for use in the method are disclosed. The oligonucleotide analog (i) has a nuclease-resistant backbone, (ii) is capable of uptake by the cells, (iii) contains between 8-40 nucleotide bases, and (iv) has a sequence of at least 8 bases complementary to a region of the virus' positive strand RNA genome that includes at least a portion of SEQ ID NOS:1-4. Exposure of cells infected with aflavivirusto the analog is effective to form within the cells, a heteroduplex structure composed of the virus ssRNA and the oligonucleotide, characterized by a Tm of dissociation of at least 45° C., and having disrupted base pairing between the virus' 5′ and 3′ cyclization sequences.
REFERENCES:
patent: 2003/0087851 (2003-05-01), Takaku et al.
patent: WO92/03454 (1992-03-01), None
patent: WO 9833904 (1998-08-01), None
patent: WO 0078341 (2000-12-01), None
patent: WO 0192512 (2001-12-01), None
patent: WO02/068637 (2002-09-01), None
patent: WO02/081495 (2002-10-01), None
patent: WO03/033657 (2003-04-01), None
Monia et al., “Nuclease Resistance And Antisense Activity of Modified Oligonucleotides Targeted to Ha-ras,” The Journal of Biological Chemistry, vol. 271, No. 24, 14533-14540 (1996).
Raviprakash et al., “Inhibition of dengue virus by novel, modified antisense oligonucleotides,” Journal of Virology, vol. 69, No. 1, pp. 69-74 (1995).
3olig8.rng results 16, 17, 18, 19, 20, 21, 22, 23.
3olig8.rge results 5, 6, 7, 17, 18, 19, 35, 36.
Result 44, 3.oli8.rge.
Deas et al., “Inhibition of Flavivirus Infections by Antisense Oluigomers Specifically Suppressing Viral Translation and RNA Replication,” Journal of Virology, vol. 79, No. 8 (2005).
22.rge results 6, 7; Takegami et al., “Nucleotide sequence at the #′ end of Japanese encephalitis virus genomic RNA,” Virology, vol. 152, Issue 2 (1986), p. 483-6.
22.rng, result 8.
Raviprakash et al., “Inhibition of Dengue Virus by Novel, Modified Antisense Oligonucleotides,” Journal of Virology, vol. 69, No. 1, pp. 69-74 (1995).
Abe et al.,Antiviral Chemistry and Chemotherapy, 9(3):253-262 (1998).
Agrawal et al.Proc Natl Aced Sci U S A., 87(4):1401-5 (1990).
Blommers et al.,Nucleic Acids Res22(20): 4187-94 (1994).
Bonham et al.,Nucleic Acids Res., 23(7):1197-203 (1995).
Boudvillain et al.,Biochemistry36(10):2925-31 (1997).
Branch, Andrea D.,TIBS, 23:45-50 (1998).
Brinton, M.A.,Annu. Rev. Microbiol., 56:371-402 (2002).
Corver Jeroen et al.,Jornal of Virology, 77(3):2265-2270 (2003).
Dagle et al.,Nucleic Acids Res., 28(10): 2153-7 (2000).
Ding, D., et al.,Nucleic Acids Res24(2):354-60, (1996).
Database Geneseq Online “WNV DNAzyme Seq ID No. 20601” Retrieved from EBI Database Accession No. ACN20585 Abstract (2004).
Database Geneseq Online “MNV DNAzyme Seq ID No. 21825” Database Accession No. ACN21809 Abstract (2004).
Database Geneseq Online “WNV Minus Starand DNAzyme Seq ID No. 32671” Database Accession No. ACN32655 Abstract (2004).
Database Geneseq Online “WNV Minus Starand DNAzyme Seq ID No. 333989” Database Accession No. ACN33973 Abstract (2004).
Enserink, M.,Science, 297(5589): 1988-1989 (2002).
Felgner et al.,PNAS, 84(21): 7413-7 (1987).
Gait et al.J Chem Soc[Perkin 1] 0(14): 1684-6 (1974).
Gee et al.,Antisense Nucleic Acid Drug Dev8(2):103-11 (1998).
Gritsun et al.,Antiviral Research, 57(1-2):129-146 (2003).
Hahn et al.,Journal of Molecular Biology, 198(1):33-41 (1987).
Hayes, E.B. and Gubler, D.J., Pediatric Infect. Dis.J., 11(4):311-317 (1992).
International Search Report for PCT/US04/025335 published as WO 2005/030800 (A3).
Khromykh et al.,Journal of Virology, 75(14):6719-6728 (2001).
Lesnikowski et al.,Nucleic Acids Res., 18(8): 2109-15 (1990).
Leyssen et al.,Clin. Microbiol. Rev., 13(1):67-82 (2000).
Li et al.,Journal of Virology, 76(23):11989-12000 (2002).
Mertes, M. P. and E. A. Coats,J Med Chem., 12(1): 154-7 (1969).
Mongkolsapaya et al.,Nat. Med., 9(7):921-927 (2003).
Morrey et al.,Antiviral Res., 55(1):107-16 (2002).
Moulton et al.,Bioconjug Chem., 15(2): 290-9 (2004).
Partridge et al.,Antisense Research&Development, 6(3):169-175 (1996).
Proutski et al.,Nucleic Acids Res., 25(6):1194-1202 (1997).
Scherret et al.,Emerging Infect. Dis., 7(4):697-705 (2001).
Summerton, J. and D. Weller,Antisense Nucleic Acid Drug Dev., 7(3):187-95 (1997).
Ternovoi et al.,Emerging Infect. Dis., 9(6):743-746 (2003).
Toulme et al.,Biochimie, 78(7): 663-73 (1996).
Wang et al.,Antimicrobial Agents and Chemotherapy, 45(4):1043-1052 (2001).
You et al.,The Journal of Biological Chemistry, 276(19):15581-15591 (2001).
Zeng et al.,Journal of Virology, 72(9):7510-7522 (1998).
Iversen Patrick L.
Stein David A.
AVI BioPharma Inc.
Horning Michelle
Lucas Zachariah
Seed IP Law Group PLLC
LandOfFree
Oligonucleotide analog and method for treating flavivirus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotide analog and method for treating flavivirus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotide analog and method for treating flavivirus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4157460